Featuring a discussion on recent clinical trial data on the use
of FLT3 inhibitors in the management of acute myeloid leukemia with
Dr Keith Pratz, including the following topics:
Targeting FLT3 in Acute Myeloid Leukemia (AML) — Keith W Pratz,
MD (0:00)
Case: A man in his late 50s with AML and a FLT3-ITD mutation
receives midostaurin and 7 + 3 chemotherapy followed by an
allogeneic transplant and maintenance sorafenib (23:52)
Case: A woman in her late 60s with hypertension and diabetes is
diagnosed with AML and FLT3-ITD, IDH2, NPM1 and NRAS mutations
(25:41)
Case: A woman in her early 80s with AML with FLT3-TKD and NPM1
mutations receives single-agent gilteritinib (27:52)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.